Medtronic to put UPI out of business with Advanced Uro-Solutions?

http://finance.yahoo.com/news/medtronic-acquires-advanced-uro-solutions-133201292.html

Medtronic plc (MDT) today announced that it has acquired Advanced Uro-Solutions, a privately-held developer of neurostimulation products for the treatment of bladder control issues based in Elizabethton, Tennessee. Terms of the acquisition agreement, which closed in December 2014, were not disclosed.

Advanced Uro-Solutions develops and manufactures the NURO(TM) percutaneous tibial nerve stimulation system, which consists of a small external stimulator and a single, reusable lead to provide temporary stimulation to the tibial nerve. This therapy is 510(k) cleared by the FDA to treat patients with overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Medtronic is preparing to launch the NURO system in the U.S. within the next 12 months.

More than 37 million adults in the United States - one in six - suffer from OAB.1,2 By 2018, it is estimated that 546 million people worldwide will be affected by OAB.3

"The acquisition of Advanced Uro-Solutions expands Medtronic`s portfolio of treatment options for those suffering from chronic symptoms of overactive bladder," said Linnea Burman, vice president and general manager, gastro/urology therapies at Medtronic. "Medtronic continues to invest in fully-implantable bladder control and bowel control therapies, and the addition of the NURO system to our existing portfolio of products will introduce more people suffering from bladder control issues to the benefits of neuromodulation."

Since 2009, Advanced Uro-Solutions has been led by two founders, Dr. Brent Laing and Dr. John Green.

"Studies show that roughly 80 percent of patients prescribed oral medications to treat their OAB symptoms have stopped taking them at 12 months, and Medtronic shares our commitment to advancing neuromodulation and increasing patient access to advanced solutions intended to treat their symptoms," said Dr. John Green, former chairman and CEO of Advanced Uro-Solutions. "We are excited to take this step toward making this important therapy available to patients around the world."

Medtronic developed and leads the field of neuromodulation, the targeted and regulated delivery of electrical pulses and pharmaceuticals to specific sites in the nervous system. The company`s Neuromodulation division includes implantable neurostimulation and targeted drug delivery systems for the management of chronic pain, common movement disorders, spasticity and urologic and gastrointestinal disorders.

Medtronic will include revenue from the Advanced Uro-Solutions product line as part of the Neuromodulation division within the Restorative Therapies Group segment. The transaction is expected to meet Medtronic`s long-term financial metrics, and the annualized earnings impact of this acquisition is not expected to be material.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Doctor files $15 million suit
By Thomas Wilson
STAR STAFF
twilson@starhq.com

An Elizabethton obstetrician has filed a $15 million lawsuit against three physicians including two local doctors whom she alleges sought to destroy her medical practice.
Filed Thursday in Carter County Circuit Court, the lawsuit names Drs. John D. Green and Brent D. Laing of First Medical Group in Elizabethton as defendants against plaintiff Dr. Juliet K. Markham. The lawsuit also names Dr. William A. Block Jr., of ETSU Physicians Obstetrics and Gynecology, 325 N. State of Franklin Road, Johnson City, as a defendant.
According to the lawsuit, Markham applied for obstetric and gynecology privileges at Sycamore Shoals Hospital in June of 2001. The lawsuit states when Markham approached Green and Laing to establish a call schedule she was allegedly told "she was not wanted here" and "you are a woman and will take all of our business". The lawsuit contends the doctors refused to share call with Markham.
The lawsuit alleges Block - identified as a "good friend" of Green - began harassing Markham regarding medical procedures at the Johnson City Medical Center Hospital. Block allegedly told Markham "I'm going to get you" while he was attending a patient in labor, the lawsuit reads.
The lawsuit further reads that during a meeting in August of 2001, Laing allegedly told Markham he had "substantial influence" and could make life "easy or difficult" for her. He also allegedly told Markham she was inadequately trained, in his opinion, although she had completed an accredited residence, the lawsuit contends. Laing allegedly offered her a position in his office as nurse practitioner, which she refused since her own medical practice was doing well, the lawsuit reads.
At the time of the meeting with Laing, Markham also had practice privileges at the Johnson City Medical Center Hospital according to the lawsuit. In January 2002, Markham received obstetric privileges at Sycamore Shoals, but her gynecological privileges she had applied for at the same time were lost. Her OB privileges were delayed for 7 months. The lawsuit identifies Dr. Laing as being chairman of the committee approving the privileges.
Markham passed her Ob-Gyn board certification in June 2002. The lawsuit alleges Block further harassed her, and, as a result of his alleged actions, her privileges were suspended in November 2002. After taking reassurances she could take her oral board examinations, she entered into mentoring arrangement and her privileges at JCMCH were reinstated June 19, 2003.
However, the lawsuit reads that contrary to assurances given Markham by doctors and committees at JCMCH, she was ruled not eligible to take her oral board exams by the American Board of Obstetrics and Gynecology since she had mentored cases.
The lawsuit reads when practice privileges are obtained at any MSHA facility, it does not automatically grant privileges at all other MSHA facilities. Ed Herbert, vice president of marketing for Mountain States Health Alliance (MSHA), said Thursday afternoon that physicians were required to apply for and receive practicing privileges at each MSHA facility. He declined comment on the status of practice privileges for any physician party to Markham's lawsuit citing professional confidentiality agreements between hospitals and medical professionals. MSHA owns both JCMCH and Sycamore Shoals Hospital, but the lawsuit did not name any of the organization's facilities or personnel as defendants.
Markham had her privileges reinstated at Sycamore Shoals on Dec. 15, 2003. She alleges the harassment by Green continued after she performed an emergency Cesarean section on a patient that was discussed with her mentoring doctor.
The lawsuit alleges one of the defendants breached peer review confidentiality by making a report to Sycamore Shoals Hospital administrator outside the proper channels. Markham's complaint also alleges that since she has been on the mentoring program, there has been a "false and malicious report filed by one of the defendants that an immediate investigation" conducted by another physician found was "baseless".
Regarding Sycamore Shoals Hospital, the lawsuit reads that a block schedule arrangement has been established that has substantially reduced operating time available to Markham and her mentoring physician. The suit reads Drs. Green and Laing are permitted 24 hours per week of block time while she and her mentor are given only two hours per week. The practice represents intentional interference and restraint of trade, the lawsuit alleges.
The lawsuit alleges Laing and Green defamed Markham, conspired to damage her practice, interfered with her peer process review and committed the alleged acts with malice for the purpose of economic gain. The lawsuit further alleges Block defamed Markham, conspired to damage her practice and used his position in the peer review process at JCMCH to initiate a bad faith peer review against Markham.
The lawsuit reads that the alleged actions represent a "civil conspiracy as the goal was the common purpose to destroy the reputation and practice of Dr. Markham".
Markham seeks $5 million in compensatory damages and $10 million in punitive damages. She asks for a jury to hear the case and requests triple damages be awarded to Markham in accordance with the Tennessee Consumer Protection Act. She also seeks to be reinstated on the medical staff of JCMC and Sycamore Shoals hospitals.
Attorney Ralph M. Bard of Tullahoma filed the lawsuit on behalf of Markham. A voice mail message left at the office of Green and Laing was not returned Thursday night. Block was not immediately available for comment Thursday.
 




http://finance.yahoo.com/news/medtronic-acquires-advanced-uro-solutions-133201292.html

Medtronic plc (MDT) today announced that it has acquired Advanced Uro-Solutions, a privately-held developer of neurostimulation products for the treatment of bladder control issues based in Elizabethton, Tennessee. Terms of the acquisition agreement, which closed in December 2014, were not disclosed.

Advanced Uro-Solutions develops and manufactures the NURO(TM) percutaneous tibial nerve stimulation system, which consists of a small external stimulator and a single, reusable lead to provide temporary stimulation to the tibial nerve. This therapy is 510(k) cleared by the FDA to treat patients with overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Medtronic is preparing to launch the NURO system in the U.S. within the next 12 months.

More than 37 million adults in the United States - one in six - suffer from OAB.1,2 By 2018, it is estimated that 546 million people worldwide will be affected by OAB.3

"The acquisition of Advanced Uro-Solutions expands Medtronic`s portfolio of treatment options for those suffering from chronic symptoms of overactive bladder," said Linnea Burman, vice president and general manager, gastro/urology therapies at Medtronic. "Medtronic continues to invest in fully-implantable bladder control and bowel control therapies, and the addition of the NURO system to our existing portfolio of products will introduce more people suffering from bladder control issues to the benefits of neuromodulation."

Since 2009, Advanced Uro-Solutions has been led by two founders, Dr. Brent Laing and Dr. John Green.

"Studies show that roughly 80 percent of patients prescribed oral medications to treat their OAB symptoms have stopped taking them at 12 months, and Medtronic shares our commitment to advancing neuromodulation and increasing patient access to advanced solutions intended to treat their symptoms," said Dr. John Green, former chairman and CEO of Advanced Uro-Solutions. "We are excited to take this step toward making this important therapy available to patients around the world."

Medtronic developed and leads the field of neuromodulation, the targeted and regulated delivery of electrical pulses and pharmaceuticals to specific sites in the nervous system. The company`s Neuromodulation division includes implantable neurostimulation and targeted drug delivery systems for the management of chronic pain, common movement disorders, spasticity and urologic and gastrointestinal disorders.

Medtronic will include revenue from the Advanced Uro-Solutions product line as part of the Neuromodulation division within the Restorative Therapies Group segment. The transaction is expected to meet Medtronic`s long-term financial metrics, and the annualized earnings impact of this acquisition is not expected to be material.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

Isn't this the physician that committed Medicare Fraud by doing PTNS is nursing home facilities until his nurse reported him?
He was a HUGE customer for UPI/Tim M.
 












Smarten up you filthy moron. Kevin Roche just bought 50,000 shares of Uroplasty. Do you think for a moment...no, a goddamn nanosecond...that he didn't know that Medtronic bought NURO back in December when he bought his Uroplasty shares. Of course he knew. It's a small business community. What does that tell you? Does that tell you that Uroplasty is going out of business because of this purchase? Of course it doesn't! Jesus, you people...

He purchased the shares so he could write-off the LOSS to offset his income. You Dumbass.
 




I am not sure who some of you are who are posting here. However, I do not believe my territory will be materially impacted by the NURO. Urgent PC continues to be readily embraced, and utilization continues to increase. Yes, NURO is a competing product. But it also increases the awareness of PTNS, which will not be a bad thing for Urgent PC. Maybe I'm drinking the koolaid. Maybe not. In any case, I figure we just need to put our noses to the grindstone and get to work. There are a lot of Americans who suffer from the indignities of OAB, and it is our job to help them out. Let's get to work, people!

Thanks Tim.
 




Smarten up you filthy moron. Kevin Roche just bought 50,000 shares of Uroplasty. Do you think for a moment...no, a goddamn nanosecond...that he didn't know that Medtronic bought NURO back in December when he bought his Uroplasty shares. Of course he knew. It's a small business community. What does that tell you? Does that tell you that Uroplasty is going out of business because of this purchase? Of course it doesn't! Jesus, you people...

Kevin Roche's investment in the 50,000 shares he bought is down 40%. Do you know what DOWN 40% means, can you comprehend that? This, before Medtronic has even launched the Nuro. Imagine, if you are capable of doing so, what would happen to his investment after Medtronic launches the Nuro….better yet, imagine, if you are capable of doing so, what would happen to his investment when Medtronic undercuts our company by $20 to $30 per treatment. Imagine, if you are capable of doing so, what would happen to our Urgentpc business in that case?

I wonder which one of us is the filthy moron? Hint: It is not those of us who are raising legitimate questions.
 




Kevin Roche's investment in the 50,000 shares he bought is down 40%. Do you know what DOWN 40% means, can you comprehend that? This, before Medtronic has even launched the Nuro. Imagine, if you are capable of doing so, what would happen to his investment after Medtronic launches the Nuro….better yet, imagine, if you are capable of doing so, what would happen to his investment when Medtronic undercuts our company by $20 to $30 per treatment. Imagine, if you are capable of doing so, what would happen to our Urgentpc business in that case?

I wonder which one of us is the filthy moron? Hint: It is not those of us who are raising legitimate questions.

First of all, who is Kevin Roche and why do we care that he was dumb enough to by 50K shares of a dog???
Here's the important issue, you either drink the company Kool-Aid and think that Medtronic is not a huge threat and you can bring value and "build your walls" around your business or you can be a realist and say with a cost of goods under a buck per treatment, they will under cut us and steal away most if not all of our business. Be realistic, how many docs would take $40-$70 profit over $70-$100, that $30 per treatment. No review or added value can make that up.
This is going to happen over the next 3-10 months, do you think you can sell enough endosheath to make up for your lost PTNS revenue??? The selling cycle is longer and you have to time it right. Do you think that a doc is going to replace good scopes with endosheath???
What other products will we be selling??? All will have ramp up time, reimbursement issues and take away from other activities.
RK and DH talk a good game, but they have not been able to walk the walk. Many people in this company think that we will be out of business in two years. I give it 50-50 odds
 




the docs I have spoken with aren't too crazy about the endosheath. they cant see plucking down $40k just so that they can save a few cleaning steps. the savings they get from the reduced number of cleaning steps take a long time to payback their investment in the endosheath. as for the containment problems with the use of the existing scopes, the docs are a bit more sympathetic to that selling point, particularly the larger practices, but still not worried enough to pluck down all that money for the endosheath. I can only speak for what I am encountering in my territory.
 








What is the word on when MDT plans to start to commercialize their NURO?

Who knows for sure, but the AUA is right around the corner. I would not be surprised if they launched there. If you look on their web site they have positions available for a noninvasive urology division. Uroplasty er Cogentix your days are numbered!!!!
 




Must be soon... there are a ton of postions posted online for it. My friend was called by MDT in California because there are no non-compete clauses there. Lucky!!!! Cali reps...RUN!!!!!
 




Must be soon... there are a ton of postions posted online for it. My friend was called by MDT in California because there are no non-compete clauses there. Lucky!!!! Cali reps...RUN!!!!!

It will be interesting to see how many make the jump. I think there will be more players in this field by the end of the year. UPC is old technology and Cogentix does not have the front end support to handle reimbursement. UPC will have little or no market share in 12 months.